In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...

Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...

in people with active lupus nephritis. In the study, a higher proportion of people treated with Gazyva/Gazyvaro plus standard therapy (mycophenolate mofetil and glucocorticoids) achieved a complete ...

Mycophenolate mofetil (MMF), originally used in transplantation, exerts its immunosuppressive effects through the inhibition of T- and B-lymphocyte proliferation. Its efficacy in SLE has been ...

Lupkynis has been approved in Japan to treat lupus nephritis, when given alongside the immunosuppressant mycophenolate ...

Drug-induced lupus is more common in men because they are given these drugs more often; however, not everyone who takes these drugs will develop the disease. Specific criteria for diagnosing ...

However, for the vast majority of lupus flares the initial treatment has to be systemic glucocorticoids. For most manifestations, prednisone at 0.25–0.5 mg/kg body weight (or equivalent ...

Objective To investigate the role of curcumin in the treatment of lupus nephritis (LN) by inhibiting the migration of neutrophils and the underlying mechanism involved. Methods Two lupus mouse models, ...